Answers are grounded in this paper and cite their sources.
Liver cancer remains a major cause of cancer mortality and the limited benefit of existing therapies leaves a clear need for new therapeutic agents. Although Angelica sinensis (AS) shows broad antitumor potential, its mechanistic basis against liver cancer remains unclear. The present study revealed that AS reduced the viability, proliferation and migration of the HepG2 human liver cancer cell line. Network pharmacology pointed to several putative targets including insulin, peroxisome proliferator‑activated receptor γ, nuclear factor κB subunit 1, estrogen receptor 1 and albumin. By combining molecular docking, molecular dynamics simulation and Cell Counting Kit‑8 cell viability screening, β‑sitosterol (BS) was identified from the candidate compounds of AS for further study, based on its stable interactions with central targets and its strong antiproliferative activity against HepG2 cells in vitro. Mechanistic assays of BS revealed that its anti‑liver cancer effect was mediated through the p53 pathway. BS treatment increased the proportion of apoptotic cells, together with increased expression of the tumor suppressor protein p53 and the pro‑apoptotic proteins Bax and Caspase‑3, and reduced expression of the anti‑apoptotic protein Bcl‑2. Co‑treatment with pifithrin‑α hydrobromide, a p53 inhibitor, partly reduced the proportion of apoptotic cells and partly reversed these changes in protein expression, confirming a p53‑dependent mechanism. The present study clarified the mechanisms by which AS, and its active component BS, suppress the proliferation and migration of liver cancer cells and trigger apoptosis through the modulation of the p53 pathway. These results support AS and BS as promising leads for development of plant‑derived therapies against liver cancer.
No takes yet. Share an insight, caveat, or question.
Du et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: